This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Loy, J. K. Articles by Durham, S. K. Search for Related Content PubMed PubMed Citation Articles by Loy, J. K. Articles by Durham, S. K. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Oncostatin M: Development of a Pleiotropic Cytokine

Department of Experimental Pathology, Bristol-Myers Squibb, Princeton, New Jersey

Thomas J. Davidson

Drug Safety Evaluation, Bristol-Myers Squibb, Syracuse, New York

Karen K. Berry

Animal Modeling, Bristol-Myers Squibb, Princeton, New Jersey

John F. Macmaster

Animal Modeling, Bristol-Myers Squibb, Princeton, New Jersey

Bharat Danle

Drug Safety Evaluation, Bristol-Myers Squibb, Syracuse, New York

Stephen K. Durham

Department of Experimental Pathology, Bristol-Myers Squibb, Princeton, New Jersey

Oncostatin M (OM) is a member of the interleukin-6 (IL-6) cytokine subfamily. The binding of OM to its receptor initiates signal transduction through JAK-signal transducers and activators of transcription (STAT) pathways and activates transcription activators through mitogen-activated protein (MAP) kinases. Results of in vitro assays documented that OM modulates cytokine expression and alters the production of proteases that down-regulate inflammation. Administration of OM to lipopolysaccharide (LPS)-challenged mice lowered serum tumor necrosis factor- (TNF-) levels and decreased the lethal effects of LPS administration. OM also reduced inflammation in animal models of human disease, including inflammatory bowel disease, antibody-induced arthritis, and experimental autoimmune encephalomyelitis. Preclinical safety studies have been conducted in the mouse and monkey. Mice were administered OM (subcutaneously) at 72, 360, or 1,560 µg/kg/day in a 2-wk toxicity study. Decreased body weights occurred at 1,560 µg/kg. Drug-related changes at 360 and 1,560 µg/kg consisted of dermal irritation at the injection site, leukopenia, and thymic lymphoid depletion; all changes were reversible following a 2-wk recovery period. In a 2-wk subcutaneous study in monkeys, OM was administered at 1, 5, 15, 45, or 150 µg/kg/day. At all doses there was reversible, transient inappetence and dermal irritation at the injection site. Drug-related changes at 5, 15, 45, and 150 µg/kg consisted of reversible elevations in both serum amyloid A and IL-6, and reversible thymic lymphoid depletion. Transient increases in body temperature occurred at 15, 45, and 150 µg/kg. The observed spectrum of immunomodulatory effects suggests that OM may have therapeutic utility in treating chronic inflammatory diseases.

Key Words: Interleukin-61 inflammation • anti-inflammatory • immunomodulatory • safety assessment

References

• Bamber B., Reife RA, Haugen HS, and Clegg CH (1998). Oncostatin M stimulates excessive extracellular matrix accumulation in a transgenic mouse model of connective tissue disease. J. Mol. Med. 76: 61-69.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Brown TJ, Rowe JM, Liu J., and Shoyab M. (1991). Regulation of IL-6 expression by oncostatin M J. Immunol. 147: 2175-2180.[Abstract]
• Bruce AG, Linsley PS, and Rose TM (1992). Oncostatin M. Prog. Growth Factor Res. 4: 157-170.[CrossRef][Medline] [Order article via Infotrieve]
• Camargo CA, Madden JF, Gao W., Selvan R., and Clavien P-A. (1997). Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 26: 1513-1520.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cichy J., Potempa J., Chawla RK, and Travis J. (1995). Regulation of alpha 1-antichymotrypsin synthesis in cells of epithelial origin. FEBS Lett. 359: 262-266.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cichy J., Potempa J., Chawla RK, and Travis J. (1995). Stimulatory effect of inflammatory cytokines on alpha 1-antichymotrypsin expression in human lung-derived epithelial cells. J. Clin. Invest. 95: 2729-2733.[Web of Science][Medline] [Order article via Infotrieve]
• Cichy J., Rose-John S., and Travis J. (1998). Oncostatin M, leukaemia-inhibitory factor and interleukin 6 trigger different effects on alpha 1-proteinase inhibitor synthesis in human lung-derived epithelial cells. Biochem. J. 329(2): 335-339.[Web of Science][Medline] [Order article via Infotrieve]
• Cooper HS, Murthy SN, Shah RS, and Sedergran DJ (1993). Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69: 238-249.[Web of Science][Medline] [Order article via Infotrieve]
• Duncan MR, Hasan A., and Berman B. (1995). Oncostatin M stimulates collagen and glycosaminoglycan production by cultured normal dermal fibroblasts: Insensitivity of sclerodermal and keloidal fibroblasts. J. Investig. Dermatol. 104: 128-133.
• Encinas JA, Lees MB, Sobel RA, Symonowicz C., Greer JM, Shovlin CL, Weiner HL, Seidman CE, Seidman JG (1996). Genetic analysis of susceptibility to experimental autoimmune encephalomyelitis in a cross between SJL/J and B10.S mice. J. Immunol. 157: 2186-2192.[Abstract]
• Engler R. (1995). Acute-phase proteins in inflammation. CR Seances Soc. Biol. Fil. 189: 563-578.[Medline] [Order article via Infotrieve]
• Gearing DP and Bruce AG (1992). Oncostatin M binds the high-affinity leukemia inhibitory factor receptor. New Biol. 4: 61-65.[Web of Science][Medline] [Order article via Infotrieve]
• Hara T., Ichihara M., Yoshimura A., and Miyajima A. (1997). Cloning and biological activity of murine oncostatin M. Leukemia 11(suppl. 3): 449-450.[Medline] [Order article via Infotrieve]
• Lindberg RA, Juan TS, Welcher AA, Sun Y., Cupples R., Guthrie B., and Fletcher FA (1998). Cloning and characterization of a specific receptor for mouse oncostatin M. Mol. Cell Biol. 18: 3357-3367.[Abstract/Free Full Text]
• Liu J., Modrell B., Aruffo A., Marken JS, Taga T., Yasukawa K., Murakami M., Kishimoto T., and Shoyab-M ( 1992). Interleukin-6 signal transducer gp 130 mediates oncostatin M signaling. J. Biol. Chem. 267: 16763-16766.[Abstract/Free Full Text]
• Liu J., Modrell B., Aruffo A., Scharnowske S., and Shoyab M. (1994). Interactions between oncostatin M and the IL-6 signal transducer, gp 130. Cytokine 6: 272-278.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Nemoto O., Yamada H., Mukaida M., and Shimmei M. (1996). Stimulation of TIMP-1 production by oncostatin M in human articular cartilage. Arthritis Rheum. 39: 560-566.[Web of Science][Medline] [Order article via Infotrieve]
• Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y., and Nakaya R. (1990). A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702.[Web of Science][Medline] [Order article via Infotrieve]
• Piquet-Pellorce C., Grey L., Mereau A., and Heath JK (1994). Are LIF and related cytokines functionally equivalent? Exp. Cell Res. 213: 340-347.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Richards CD and Agro A. (1994). Interaction between oncostatin M, interleukin 1 and prostaglandin E2 in induction of IL-6 expression in human fibroblasts. Cytokine 6: 40-47.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Richards CD, Kerr C., Tanaka M. Hara T., Atsushi M., Pennica D., Botelho F., and Langdon CM (1997). Regulation of tissue inhibitor of metalloproteinase-1 in fibroblasts and acute phase proteins in hepatocytes in vitro by mouse oncostatin M, cardiotrophin-1, and IL-6 J. Immunol. 157: 2341-2347.
• Richards CD, Langdon C., Botelho F., Brown TJ, and Agro A. (1996). Oncostatin M inhibits IL-1-induced expression of IL-8 and granulocyte-macrophage colony-stimulating factor by synovial and lung fibroblasts. J. Immunol. 156: 343-349.[Abstract]
• Richards CD and Shoyab M. (1993). The role of oncostatin M in the phase response. In: Acute Phase Proteins: Molecular Biology, Biochemistry and Clinical Applications. A Mackiewitz, I Kushner, and H Baumann (eds). CRC Press, Inc., Boca Raton, Florida, pp. 321-327.
• Richards CD, Shoyab M., Brown TJ, and Gauldie J. (1993). Selective regulation of tissue inhibitor of metalloproteinases (TIMP-1) by oncostatin M in fibroblasts in culture J. Immunol. 150: 5596-5603.[Abstract]
• Seitz M., Dewald B., Gerber N., and Baggiolini M. (1991). Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis. J. Clin. Invest. 87: 463-469.[Web of Science][Medline] [Order article via Infotrieve]
• Steel DM and Whitehead AS (1994). The major acute phase reactants: C-Reactive protein, serum amyloid P component and serum amyloid A protein. Immunol. Today 15: 81-88.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Terato K., Harper DS, Griffiths MM, Hasty DL, Ye XJ, Cremer MA, and Seyer JM (1995). Collagen-induced arthritis in mice: Synergistic effect of E. coli lipopolysaccharide bypassed epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 22: 137-147.[Web of Science][Medline] [Order article via Infotrieve]
• Terato K., Hasty KA, Reife RA, Cremer MA, Kang AH, and Stuart JM (1992). Induction of arthritis with monoclonal antibodies to collagen. J. Immunol. 148: 2103-2108.[Abstract]
• Wallace PM, MacMaster JF, Rillema JR, Peng J., Burstein SA, Shoyab M. (1995). Thrombocytopoietic properties of oncostatin M. Blood 86: 1310-1315.[Abstract/Free Full Text]
• Wallace PM, MacMaster JF, Rillema JR, Rouleau KA, Hanson MB, Burstein SA, and Shoyab M. (1995). In vivo properties of oncostatin M. Ann. NY Acad. Sci. 762: 42-54.[Medline] [Order article via Infotrieve]
• Wallace PM, MacMaster JF, Rouleau KA, Brown TJ, Loy JK, Donaldson KL, and Wahl AF (1998). Regulation of inflammatory responses by oncostatin M. J. Immunol. (in press).
• Xing M., Gauldie J., Cox G., Baumann H., Joordana M., Xue-Feng L., and Achong MK (1998). IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101(2): 311-320.[Web of Science][Medline] [Order article via Infotrieve]
• Xu W., Firestein R., Taetle R., Kaushansky K., and Zvaifler N. (1989). Cytokines in inflammatory arthritis: Granulocyte colony-stimulating factor in rheumatoid synovial effusions. J. Clin. Invest. 83: 876-882.[Web of Science][Medline] [Order article via Infotrieve]
• Yoshimura A., Ichihara M., Kinjyo I., Moriyama M., Copeland NG, Gilbert DJ, Jenkins NA, Hara T., and Miyajima A. (1996). Mouse oncostatin M: An immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway. EMBO J. 15(5): 1055-1063.[Web of Science][Medline] [Order article via Infotrieve]
• Zarling JM, Shoyab M., Marquardt H., Hanson MB, Lioubin MN, and Todaro GJ (1986). Oncostatin M: A growth regulator produced by differentiated histiocyte lymphoma cells. Proc. Natl. Acad. Sci. USA 83: 9739-9743.[Abstract/Free Full Text]
• Zhou X., Gauldie J., Cox G., Baumann H., Jordana M., Lei X-F., and Achong MK (1998). IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses J. Clin. Invest. 101(2): 311-320.[Web of Science][Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 27, No. 2, 151-155 (1999)
DOI: 10.1177/019262339902700201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Demyanets, C. Kaun, K. Rychli, G. Rega, S. Pfaffenberger, T. Afonyushkin, V. N. Bochkov, G. Maurer, K. Huber, and J. Wojta The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1962 - H1968. [Abstract] [Full Text] [PDF]

				G. Rega, C. Kaun, T.W. Weiss, S. Demyanets, G. Zorn, S.P. Kastl, S. Steiner, D. Seidinger, C.W. Kopp, M. Frey, et al. Inflammatory Cytokines Interleukin-6 and Oncostatin M Induce Plasminogen Activator Inhibitor-1 in Human Adipose Tissue Circulation, April 19, 2005; 111(15): 1938 - 1945. [Abstract] [Full Text] [PDF]

				C. Boileau, M. Houde, G. Dulude, C. H. Clegg, and C. Perreault Regulation of Extrathymic T Cell Development and Turnover by Oncostatin M J. Immunol., June 1, 2000; 164(11): 5713 - 5720. [Abstract] [Full Text] [PDF]

				Y. Wang, O. Robledo, E. Kinzie, F. Blanchard, C. Richards, A. Miyajima, and H. Baumann Receptor Subunit-specific Action of Oncostatin M in Hepatic Cells and Its Modulation by Leukemia Inhibitory Factor J. Biol. Chem., August 11, 2000; 275(33): 25273 - 25285. [Abstract] [Full Text] [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Loy, J. K. Articles by Durham, S. K. Search for Related Content PubMed PubMed Citation Articles by Loy, J. K. Articles by Durham, S. K. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?